ImmunityBio (IBRX) News Today → Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad) Free IBRX Stock Alerts $6.10 +0.01 (+0.16%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 8 at 5:50 AM | marketbeat.com739,808 Shares in ImmunityBio, Inc. (NASDAQ:IBRX) Acquired by Rafferty Asset Management LLCRafferty Asset Management LLC bought a new position in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 739,808 shares of the coJune 7 at 9:13 AM | businesswire.comImmunityBio Announces 2024 Annual Meeting of Stockholders with Company UpdateJune 6 at 3:09 PM | seekingalpha.comImmunityBio: Anktiva's Launch Demands A ReassessmentJune 6 at 11:47 AM | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Gap Down to $6.36ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $6.36June 5 at 8:04 AM | americanbankingnews.comImmunityBio (NASDAQ:IBRX) Shares Down 3.3% June 3, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Down 3.3%ImmunityBio (NASDAQ:IBRX) Trading Down 3.3%June 2, 2024 | americanbankingnews.comImmunityBio (NASDAQ:IBRX) Trading Up 4.4%May 31, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Up 4.4%ImmunityBio (NASDAQ:IBRX) Trading Up 4.4%May 17, 2024 | benzinga.comWhat the Options Market Tells Us About ImmunityBioMay 17, 2024 | businesswire.comConnecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday PodcastMay 16, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 4.2% ImmunityBio (NASDAQ:IBRX) Shares Down 4.2%May 13, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 8.9%ImmunityBio (NASDAQ:IBRX) Stock Price Up 8.9%May 11, 2024 | finance.yahoo.comImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 10, 2024 | investorplace.comIBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | investorplace.comThe 3 Best Bargain Stocks to Buy in May 2024May 8, 2024 | benzinga.comLatest News for ImmunityBio Stock (NASDAQ:IBRX)May 7, 2024 | finance.yahoo.comImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®May 7, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Gap Up to $7.81ImmunityBio (NASDAQ:IBRX) Shares Gap Up to $7.81May 6, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 12.6% ImmunityBio (NASDAQ:IBRX) Shares Down 12.6%May 6, 2024 | investorplace.comEven Worse than Gamestop? 3 Meme Stocks That Are Screaming SellsMay 3, 2024 | msn.comSerum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio's Bladder Cancer Combo TherapyMay 2, 2024 | businesswire.comImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer TypesMay 1, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 11.4%ImmunityBio (NASDAQ:IBRX) Shares Up 11.4%May 1, 2024 | theglobeandmail.comPromising Outlook as Biotech Sector Advances Cancer Treatments Amidst Rising DiagnosesApril 30, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 6.3% ImmunityBio (NASDAQ:IBRX) Stock Price Down 6.3%April 30, 2024 | businesswire.comImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological AssociationApril 29, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Sets New 12-Month High Following Analyst UpgradeImmunityBio (NASDAQ:IBRX) Sets New 12-Month High Following Analyst UpgradeApril 29, 2024 | marketbeat.comPiper Sandler Increases ImmunityBio (NASDAQ:IBRX) Price Target to $6.00Piper Sandler lifted their price objective on shares of ImmunityBio from $5.00 to $6.00 and gave the stock a "neutral" rating in a report on Monday.April 26, 2024 | msn.comWhat's Going On With ImmunityBio Stock?April 26, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Sees Strong Trading VolumeImmunityBio (NASDAQ:IBRX) Sees Strong Trading VolumeApril 25, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading 4.6% Higher ImmunityBio (NASDAQ:IBRX) Trading Up 4.6%April 25, 2024 | bizjournals.comFDA approves local company's bladder cancer drugApril 25, 2024 | businesswire.comImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung CancerApril 24, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - IBRXApril 24, 2024 | msn.comFDA approves bladder cancer treatment by Culver City companyApril 23, 2024 | finance.yahoo.comFDA Approves ImmunityBio's Bladder Cancer Drug, Stock RalliesApril 23, 2024 | seekingalpha.comImmunityBio: Anktiva Approval Opens Up A World Of Possibilities, Risks And Potential GainsApril 23, 2024 | marketbeat.comImmunityBio Target of Unusually High Options Trading (NASDAQ:IBRX)ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock traders bought 23,649 call options on the stock. This represents an increase of approximately 308% compared to the average volume of 5,801 call options.April 23, 2024 | seekingalpha.comImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer BattleApril 23, 2024 | msn.comBiggest stock movers today: IBRX, NVS, and moreApril 23, 2024 | msn.comImmunityBio stock jumps as FDA clears bladder cancer therapyApril 22, 2024 | businesswire.comImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder CancerApril 22, 2024 | reuters.comU.S. FDA approves ImmunityBio's bladder cancer therapyApril 22, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 4% ImmunityBio (NASDAQ:IBRX) Shares Down 4%April 19, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Up 4.5%ImmunityBio (NASDAQ:IBRX) Stock Price Up 4.5%April 17, 2024 | finance.yahoo.comImmunityBio, Inc. (IBRX) Stock Historical Prices & Data - Yahoo FinanceApril 13, 2024 | marketbeat.comVanguard Group Inc. Increases Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)Vanguard Group Inc. raised its position in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 42.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,675,687 shares of the company's stock after acquiring an additional 4April 12, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Down 8.1%ImmunityBio (NASDAQ:IBRX) Stock Price Down 8.1%April 11, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Up 3.7%ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.7%April 3, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 8%ImmunityBio (NASDAQ:IBRX) Shares Up 8% Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Time is Running Out - June 25th Deadline Approaching! (Ad)If you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay. See all the details you need here. IBRX Media Mentions By Week IBRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IBRX News Sentiment▼0.330.73▲Average Medical News Sentiment IBRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IBRX Articles This Week▼63▲IBRX Articles Average Week Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TGTX News HRMY News VCYT News SAGE News TSHA News FLGT News ITOS News ALEC News AURA News PGEN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IBRX) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredNvidia has Apple and Microsoft within striking rangeA small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. W...Weiss Ratings | Sponsored